Navigation Links
Lilly Reports Third-Quarter 2013 Results
Date:10/23/2013

d by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release.Alimta® (pemetrexed, Lilly)
Amyvid™  ((Florbetapir F 18 Injection, Lilly)
Axiron® (testosterone, Acrux Corp.)
Cialis® (tadalafil, Lilly)
Cymbalta® (duloxetine hydrochloride, Lilly)
Effient® (prasugrel, Lilly)
Evista® (raloxifene hydrochloride, Lilly)
Forteo® (teriparatide of recombinant DNA origin injection, Lilly)
Humalog® (insulin lispro injection of recombinant DNA origin, Lilly)
Humulin® (human insulin of recombinant DNA origin, Lilly)
Strattera® (atomoxetine hydrochloride, Lilly)
Trajenta® (linagliptin, Boehringer Ingelheim)
Zyprexa® (olanzapine, Lilly)Eli Lilly and Company Employment InformationSeptember 30, 2013December 31, 2012Worldwide Employees37,810

38,350 Eli Lilly and CompanyOperating Results  (Unaudited) – REPORTED(Dollars in millions, except per share data)Three Months EndedNine Months EndedSeptember 30,September 30,20132012

% Chg.20132012

% Chg.Total Revenue

$

5,772.6

$

5,443.3

6%$

17,304.3

$

16,646.0

4%Cost of sales1,198.11,203.6

0%3,521.63,548.2

(1)%Research and development1,377.41,342.8

3%4,055.93,815.0

6%Marketing, selling and administrative1,652.41,757.4

(6)%5,172.05,536.0

(7)%Asset impairments, restructuring and other special charges 

53.3

 

NM 

85.2 

77.1

 

11%Operating income1,544.71,086.2

42%4,469.63,669.7

22%Net interest income (expense)(7.6)(21.3)(34.9)(5
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
2. Lilly Declares Fourth-Quarter 2013 Dividend
3. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
4. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
5. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
7. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
8. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
9. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
11. Lilly Reports Second-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014  Alere Inc. (NYSE: ... tests, has appointed Juliet Cunningham as Vice ... will be responsible for driving communications with the investment ... a series of changes to increase shareholder value, it ... investors," said Namal Nawana, Chief Executive Officer. "We are ...
(Date:11/21/2014)... Calif. , Nov. 21, 2014 In ... and Performance Scrubs carried out a new product development ... industry,s very first "limited edition" lab coat , ... female professors of surgery in the world. The new ... its unisex predecessors, with a sleek envelope collar, vertical ...
(Date:11/21/2014)... CITY, Calif. , Nov. 21, 2014  Abaxis, ... company manufacturing point-of-care instruments and consumables for the medical, ... services to the veterinary and research markets in ... completion of a stock purchase agreement to acquire 100% ... United Kingdom based distribution organization. The transaction ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... 14 Merrimack Pharmaceuticals,Inc. today announced that enrollment ... 100 patients that evaluates the safety and efficacy ... rheumatoid arthritis (RA). MM-093 is a,recombinant version of ... Phase 2 study is,being conducted at 20 centers ...
... Inc.,(Amex: ILE ) announced today the completion ... II/III Study IT-A-008 investigating the Isolagen,Therapy(TM) for the ... will be administered at seven clinical sites across ... Isolagen Therapy could hold great promise for the,treatment ...
Cached Medicine Technology:Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis 2Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 2Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study 3
(Date:11/23/2014)... 23, 2014 The report, “Market ... to 2020 - Asia-Pacific” provides quantitative analysis of ... segments: minimally invasive body contouring devices, non-invasive body ... includes market size data by revenue and volume ... countries: China, Japan, South Korea, Australia and India. ...
(Date:11/23/2014)... 2014 Nearly 260 testosterone lawsuits ... deep vein thrombosis and other serious cardiovascular events ... litigation (MDL) underway in the Northern District of ... documents updated on November 17th by the U.S. ... filing of 259 lawsuits against the makers of ...
(Date:11/23/2014)... November 23, 2014 Locks-Magnetic.com, a notable ... doors. Moreover, all the new products are available at ... marketing manager is proud of the new emergency doors. ... automatically. And customers can choose from several colors. All ... high quality emergency door release is not as easy ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power ... company has announced its new collection of power suppliers. ... high quality power suppliers. All the new models come ... offer lasts until Dec. 20, 2014. , SWAccessControl.com has ... been supporting it for a long time. It is ...
(Date:11/23/2014)... Beach, CA (PRWEB) November 23, 2014 ... of American Medical Aesthetics & Wellness was recently ... Asher Milgrom, Ph.D. is president and CEO of American ... Dr. Asher Milgrom received a full scholarship to ... and the Medical School at the University of Chicago, ...
Breaking Medicine News(10 mins):Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4
... UPMC Health Plan announced it has,expanded both its ... its UPMC for Life Specialty Plan into Cameron, ... also announced the,expansion of its Medicare PPO (Preferred ... our footprint in Western Pennsylvania helps us continue ...
... poor physical function, , , TUESDAY, Jan. 22 (HealthDay News) -- If ... have a greater risk of declining physical function as you age, ... researchers report that people with the lowest blood levels of vitamin ... physical function when compared to people with the highest levels of ...
... STERIS Corporation,(NYSE: STE ) today announced that ... in the amount of $0.06 per common share. The,dividend ... at the close,of business on February 12, 2008., ... to provide a healthier today and,safer tomorrow through knowledgeable ...
... International effort should spot genes that help cause disease, ... The genomes of 1,000 people worldwide will be ... and medically relevant look at human genetic variation ever ... researchers on Tuesday, the 1000 Genomes Project will receive ...
... from the Monell Center and Tokyo University of Agriculture ... compounds from common foods that activate human bitter taste ... Biochemical and Biophysical Research Communications, provide a practical means ... in particular. , Identification of bitter taste ...
... nanotechnology, scientists from UCLA and Northwestern University have ... that is invisible to the immune system, a ... treatments for cancer and other diseases. , The ... ACS Nano, provides an example of the enormous ...
Cached Medicine News:Health News:UPMC Health Plan Expands Medicare and Special Needs Plan Into Additional Western Pennsylvania Counties 2Health News:Lack of Vitamin E Linked to Physical Decline 2Health News:Lack of Vitamin E Linked to Physical Decline 3Health News:STERIS Corporation Declares Regular Quarterly Dividend 2Health News:STERIS Corporation Declares Regular Quarterly Dividend 3Health News:Project Will Map Genomes of 1,000 People Worldwide 2Health News:Food peptides activate bitter taste receptors 2Health News:Scientists use nanomaterials to localize and control drug delivery 2Health News:Scientists use nanomaterials to localize and control drug delivery 3
RIA kit for the quantitative determination of autoantibodies to steroid 21-hydroxylase (21-OH) in serum....
6700 Reagent Reservoirs, 120 mL...
... volume for use with 4, 8, or 12 ... withdrawal of nearly all of the solution. Corners ... Made of natural virgin polystyrene containing no regrinds. ... Dimensions: 78 mm W x 152 mm L ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
Medicine Products: